Pre-IPO Brii Biosciences - Insights on Pipeline and Related Concerns
This insight mainly analyzed the core product candidates of Brii Biosciences in the pipeline (HBV, COVID-19 products and others), the competitive...
557 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
582 Views
HSCI Index Rebalance - Stock Connect Flows Coming Up
The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....
722 Views
HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities
Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...
1.1k Views
Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
763 Views